LHRH Analogue

DRUG2 trials

Sponsors

Alliance Foundation Trials, LLC., Spanish Breast Cancer Research Group

Conditions

Early Breast CancerProstate Cancer

Phase 2

Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients

Active, not recruitingNCT04293393

Spanish Breast Cancer Research GroupEarly Breast Cancer

Start: 2020-10-02End: 2033-02-28Updated: 2026-03-12

Phase 3

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

CompletedNCT03009981

Alliance Foundation Trials, LLC.Prostate Cancer

Start: 2017-03-06End: 2025-06-25Updated: 2025-12-18

Related Papers

Abstract P1-09-12: Comparative Analysis of the Oncotype DX Breast Recurrence Score® assay for Neoadjuvant Letrozole/Abemaciclib versus Chemotherapy in Stage II-III, Ki67≥20%, HR+/HER2- Breast Cancer: Insights from the GEICAM/CARABELA Trial

Clinical Cancer Research2025-06-13

Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.

Journal of Clinical Oncology2024-06-01

Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.

Journal of Clinical Oncology2024-05-293 citations

112MO Neoadjuvant study of 12 months of abemaciclib plus letrozole vs chemotherapy in HR+/HER2– highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) trial

ESMO Open2024-05-012 citations

PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)

Journal of Clinical Oncology2024-01-2438 citations

Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).

Journal of Clinical Oncology2023-06-01

LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER (AFT-19)

The Journal of Urology2023-03-233 citations

Baseline characteristics associated with PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).

Journal of Clinical Oncology2023-02-204 citations

The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.

2019-05-239 citations

A phase 3 study of androgen annihilation in high-risk biochemically relapsed prostate cancer: An Alliance Foundation trial (AFT-19).

Journal of Clinical Oncology2018-05-205 citations